last half yearly report

The last half yearly informed us of this

"Following further successful work at MIT BioInstrumentation laboratory, the Company (NAL) is currently in discussions and negotiations with a number of pharmaceutical groups who have approached Norwood Abbey in relation to the needle-free technology. The company's objective in the next year is to enter into multiple licensing and collaborative research arrangements......etc.....

Note the following:

1) with a number of pharmaceutical companies who have approached Norwood Abbey - this means approaches made to NAL from pharma firms not the other way around.

2) Looking to enter into multiple licensing and research arrangements......in other words....looking to create multiple revenue streams.

NAL further states that it's only cost going forward will be the maintenance of it's parent IP portolio.....all the expensive research has been done.

Then read the Ann of yesterday....

Makes a compelling story imo...

Then the last line from Tuesday's rather pleasant ANN:

"The latest trial results come as Norwood progresses discussions with several glonal pharmaceutical groups."


I suspect NAL will have a good day today.....(and tomorrow)

EB